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Abstract.  Human platelet thrombospondin adsorbed 
on plastic promotes attachment and spreading of hu- 
man G361 melanoma cells. Attachment is rapid, and 
spreading is maximal by 90 min with 60-90%  of the 
attached cells spread. In contrast, thrombospondin 
promotes attachment but not spreading of human C32 
melanoma cells, which attach and spread only on 
laminin substrates. The specificity of these interactions 
and the regions of the thrombospondin molecule in- 
volved in attachment and spreading were examined 
using proteolytic fragments of thrombospondin and by 
inhibition studies. The sulfated fucan, fucoidan, and 
monoclonal antibody A2.5, which is directed against 
the heparin-binding domain of thrombospondin, selec- 
tively inhibit spreading but only weakly inhibit attach- 
ment. Monoclonal antibodies against some other do- 
mains of thrombospondin, however, are potent 
inhibitors of attachment. The amino-terminal heparin- 
binding domain of thrombospondin does not promote 
attachment. Large fragments lacking the heparin- 
binding domain support attachment but not spreading 
of G361 cells. Attachment activity is lost following 
removal of the 18-kD carboxyl-terminal domain. These 
results suggest that at least two melanoma ligands are 
involved in cell attachment and spreading on throm- 
bospondin. The carboxyl-terminal region and perhaps 
other regions of the molecule bind to receptor(s) on 
the melanoma surface that promote initial attachment 
but not cell spreading. Interaction of the heparin- 
binding domain with sulfated glycoconjugates on mela- 
noma surface proteoglycans and/or sulfated glycolipids 
mediates spreading. Monoclonal antibodies A2.5 and 
C6.7 also reverse spreading of G361 cells growing on 
glass culture substrates, suggesting that binding to throm- 
bospondin mediates attachment of these melanoma 
cells in culture. 
T 
HROMBOSPONDIN is a  glycoprotein  that is  secreted 
from platelet a-granules after platelet  activation  (3, 
12). The secreted thrombospondin binds to the surface 
of activated platelets (20, 32, 47) and may mediate platelet 
aggregation  (9,  13, 26).  Thrombospondin also specifically 
supports  adhesion of erythrocytes parasitized  with malaria 
(Plasmodium falciparum) and may mediate adherence of 
parasitized  erythrocytes to melanoma and endothelial cells 
(42). As thrombospondin is secreted by several cultured cell 
lines including endothelial (29, 30, 38), melanoma (42), and 
smooth muscle cells (38), fibroblasts (22, 38), pneumocytes 
(43), macrophages, and monocytes (21), and is incorporated 
into the extracellular matrix of some of these cell lines (22, 
23, 28),  thrombospondin  may also mediate additional cell 
adhesive interactions. Some human melanoma cell lines bind 
erythrocytes  parasitized with falciparum malaria (44). Solu- 
ble thrombospondin or antibodies to thrombospondin inhibit 
adherence of parasitized erythrocytes to thrombospondin  or 
melanoma cells (42), suggesting that these cells have recep- 
tors for thrombospondin or a closely related molecule (4). 
We have examined the interaction of the human melanoma 
cell lines G361 and C32 with thrombospondin  and report 
here that thrombospondin  promotes attachment of both cell 
lines and spreading of only G361 melanoma cells. Based on 
ligand  and antibody  inhibition  and adhesive  activities  of 
thrombospondin fragments, at least two regions of the mole- 
cule are involved in attachment and spreading of G361 cells 
on surfaces coated with thrombospondin. 
Materials and Methods 
Materials 
Calcium-replete thrombospondin was  purified  from  the  supernatant  of 
thrombin-stimulated human platelets by affinity chromatography on gela- 
tin-agarose and heparin-agarose and gel filtration on Bio-gel A0.5m (17). 
The purified protein gave a single band (Mr 180,000) on electrophoresis in 
the presence of SDS and 2-mercaptoethanol (24) and was stored at -70°C 
in  Tris-buffered  saline,  pH  7.6, containing  20%  sucrose and  0.1  mM 
CaCI2.  Platelet factor 4  was purified from the heparin-bound fraction of 
the same platelet supernatants by elution from the heparin-agarose column 
with 2 M NaCI (8, 15). The platelet factor 4 was further purified by gel filtra- 
tion (15) on Biogel A0.5m. Mouse laminin isolated from the Engelbreth- 
Holm-Swarm tumor was provided by Dr. Lance Liotta (National Cancer In- 
stitute, National Institutes of Health, Bethesda, MD).  Synthetic peptides 
corresponding to the cell attachment site of fibronectin, vitronectin, and 
monoclonal antibodies 8E6 and 9G2 to vitronectin were provided by Dr. 
Erkki  Ruoslahti  (La Jolla Cancer Research Foundation,  La Jolla,  CA). 
Monoclonal antibodies to thrombospondin were provided by Dr. William 
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Figure 1.  Adsorption  of  t25I-thrombospondin onto  plastic.  ]251- 
Thrombospondin  (TSP) at 3-200 gg/ml in PBS/Ca was incubated 
for 18 h at 4°C in bacteriological plastic petri dishes. The superna- 
tant liquid was removed, and the plastic was rinsed with Tris-BSA. 
Bound radioactivity was  used to calculate the amount of throm- 
bospondin adsorbed, and is presented as the mean of triplicate de- 
terminations for each concentration, 
Frazier (Washington University School of Medicine, St. Louis,  MO). Hu- 
man von Willebrand factor was provided by Dr. Harvey Gralnick (Clinical 
Pathology  Department,  NIH).  Human plasma fibronectin was  obtained 
from Collaborative Research,  Inc., Waltham, MA. Human fibrinogen and 
fucoidan were obtained from Sigma Chemical Co., St. Louis, MO. Heparin 
was from the Upjohn Co.  (Kalamazoo,  MI). 
Cell Culture 
Human melanoma cell lines C32 (ATCC CRL 1585) and G361 (ATCC CRL 
1424) were  maintained by  monolayer  culture on 75-cm  2 tissue culture 
flasks (Costal Cambridge, MA) in RPM11640 containing 10% FBS (Gibco, 
Grand Island,  NY).  For attachment assays,  cells were passaged  at  104 
cells/cm  2 and used between days 5 and 8. 
Attachmen t Assays 
Cells were detached by replacing the medium with PBS, pH 7.2, containing 
2.5 mM EDTA and incubating for 60 min at 37°C. The cells were collected 
by centrifugation and resuspended immediately  before use in RPMI 1640 
without NaHCO3 and containing 30 mM Hepes,  pH 7.2. 
Adhesive proteins were adsorbed onto 13-mm diameter plastic disks cut 
from bacteriological  plastic dishes (Falcon 1007) (14)  by incubation with the 
proteins in PBS, pH 7.2, containing 1 mM CaCl2 for 16-24 h at 4°C.  The 
supernatant was removed and the disks  immersed in Tris-BSA (50 mM 
Tris-HCl,  110 mM  NaC1,  5  mM  CaC12, 0,1  mM  phenylmethylsulfonyl 
fluoride  (PMSF),  1% BSA 0.02%  NAN3, pH 7.8) for 30 min to minimize 
nonspecific  adhesion.  The disks were washed twice with RPMI and over- 
layed with melanoma cells at a density of 4-6  x  104/cm  2, 0.5 nil/well in 
24-well plates.  After incubation for 90 min at 37°C, the disks were washed 
by dipping six times in RPMI, fixed with 1% glutaraldehyde  in PBS, pH 
7.2, and stained with 1.5 % Giemsa. Attached and spread cells were counted 
microscopically. 
For inhibition studies,  disks coated  with thrombospondin (50 gg/mi) 
were preincubated for 30 min at 25°C in 0.4 ml of RPMI containing  the anti- 
bodies or ligands to be tested before addition of melanoma cells. Melanoma 
cells were added in 0.1 ml RPMI and incubated for 90 rain at 37°C. The 
disks were fixed with 1% glutaraldehyde  and stained  for counting. 
Thrombospondin Adsorption to Plastic 
Thrombospondin was labeled with Na 125I (ICN  Radiochemicals,  Irvine, 
CA) using Iodogen (Pierce Chemical Co., Rockford, IL) as previously  de- 
scribed (41). Immediately  before  use,  40 gCi of t~I-thrombospondin (10 
ltCi/Ixg) was applied to a 0.2-ml column of heparin-agarose (Sigma Chemi- 
cal Co.) in 20 mM Tris-buffered  saline, pH 7.6, containing 1 mM CaCI2 
and eluted  with the same buffer  containing 0.6 M  NaCI.  The repurified 
125I-thrombospondin was diluted  with unlabeled thrombospondin to final 
concentrations of 3 to 200 ltg/ml in PBS, pH 7.2,  1 mM CaC12. Incubation 
on plastic disks  was done as described for cell attachment assays.  After 
washing,  adsorbed thrombospondin was measured by counting the bound 
radioactivity. 
Limited Proteolysis of Thrombospondin 
Thrombospondin was digested with 4 U/ml reagent thrombin (provided by 
Dr. Jules Gladner, NIH), 0.05%-5% wt/wt L-l-tosylamido-2-phenylethyl- 
chloromethylketone-treated trypsin  (CooperBiomedical  Inc.,  Malvern, 
PA), or 0.5 % wt/wt chymotrypsin (67 U/mg, CooperBiomedical)  in 20 mM 
Tris-buffered  saline,  pH 7.6, containing 0.1 mM CaC12 and 0.02%  NAN3. 
Digestions  were stopped by addition of 2 mM PMSF and the digests were 
fractionated  by chromatography  on heparin-agarose (8).  The fragments 
were analyzed by electrophoresis in the presence of SDS and 2-mercapto- 
Figure 2. Adhesion of melanoma cells to surfaces coated with thrombospondin (a and d, 50 gg/ml), laminin (b and e, 25 gg/ml), or platelet 
factor 4  (c and f,  25  gg/ml),  a-c are  G361  melanoma cells applied at 4.5  x  104/cm  2.  d-f are  C32  melanoma cells applied  at 0.7  x 
104/cm  2. Incubation was for 90 min at 37°C.  Cells were fixed with 1%  glutaraldehyde and photographed using Hoffman modulation con- 
trast optics. Bar, 70 gm. 
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plastic. 
Results 
Thrombospondin Adsorption 
Adsorption of thrombospondin to bacteriological plastic was 
quantified using L25I-thrombospondin  (Fig.  1). At low con- 
centrations,  '~70%  of the added thrombospondin remains 
bound following washing with Tris-BSA buffer. At satura- 
tion, 15 ng of thrombospondin is bound per mm  2 of plastic. 
Adsorption of thrombospondin is  similar to that reported 
previously for fibronectin and other proteins (14, 40). 
Attachment and Spreading of  Melanoma Cells on 
Thrombospondin and Other Proteins 
Surfaces coated with laminin, thrombospondin, platelet fac- 
tor 4, or albumin were tested for promotion of cell attach- 
ment using C32 and G361 human melanoma cell lines. Both 
cell lines attach on all of the proteins except albumin (Fig. 
2). The cell lines differ, however, in their spreading behavior. 
G361 cells spread well on thrombospondin and laminin but 
not on platelet factor 4 substrates. C32 cells spread on lami- 
nin  substrate  but  remain  rounded on  thrombospondin or 
platelet factor 4 even after 2 h at 37°C.  G361 cells were also 
tested for attachment on surfaces coated with von Willebrand 
factor or vitronectin (data not shown), von Willebrand factor 
did not promote attachment. Surfaces coated with 50 ~tg/ml 
of vitronectin promoted attachment of G361  cells at levels 
similar to laminin or thrombospondin. Approximately 30- 
40% of the cells spread on vitronectin after 90 min. 
Kinetics for G361 melanoma cell attachment on substrates 
coated with thrombospondin or laminln are identical (Fig. 
3).  Maximal attachment is attained at 30 min. In three ex- 
periments, 60-80% of the added cells attached to both sub- 
strates. The attached cells, however, spread faster on laminin 
than on thrombospondin substrates (Fig. 3 B). 
The dependence on adsorbed protein concentration for 
the  attachment and  spreading  of G361  melanoma  cell  is 
presented in  Fig.  4.  Cell  attachment on thrombospondin 
closely parallels the adsorption isotherm for thrombospon- 
din in  Fig.  1.  Spreading  is  maximal at 50  lxg/ml  throm- 
bospondin and falls slightly at lower concentrations. 
Attachment is similar on laminln-coated substrates (Fig. 4 
C)  compared to thrombospondin-coated substrates (Fig. 4 
A) except that lower concentrations of laminin are required 
for comparable attachment activity. G361  cells also spread 
well on laminin (Fig. 4 D). Whereas platelet factor 4 also 
promotes efficient attachment (Fig. 4  C), only 20% of the 
cells spread on this  substrate even at high concentrations 
(Fig. 4 D). Furthermore, the cells that do spread are much 
less flattened than on thrombospondin or laminin. Thus at- 
tachment and spreading on thrombospondin is not due to 
contamination with platelet factor 4. 
Cell Attachment to Thrombospondin Fragments 
Thrombospondin fragments generated by limited proteolysis 
in the presence of calcium (6, 8, 25, 39) were tested for pro- 
motion of cell attachment and spreading on plastic to define 
those regions of the molecule which interact with the mela- 
noma cells. Thrombin, trypsin, and chymotrypsin digests of 
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Figure 3. Kinetics of  G361 melanoma cell attachment and spreading 
on thrombospondin and laminin. Bacteriological plastic was coated 
with thrombospondin (solid circles, 50 Ixg/ml)  or laminin (open  cir- 
cles, 20 ktg/ml) in PBS/Ca for 20 h at 4°C. The plastic was in- 
cubated for 30 min in Tris-BSA, washed twice with RPMI 1640, 
and overlayed with 4.5  x  104 melanoma cells/cm  2. At the indi- 
cated times, unattached cells were removed by washing in RPMI. 
Attached cells  were  fixed with  1%  glutaraldehyde in  PBS and 
stained with Giemsa. Attached cells (A) and percent of attached 
cells spread (B) are presented as mean  +  SD; n  =  8. 
thrombospondin were analyzed by SDS gel electrophoresis 
(Fig. 5) and adsorbed on plastic to quantify G361 melanoma 
cell attachment (Table I).  Digestion with thrombin in the 
presence of calcium selectively removes the 25-kD amino- 
terminal  heparin-binding fragment (25)  to give a  140-kD 
fragment (Fig. 5, lane a). The heparin-binding fragment, un- 
degraded thrombospondin, and  140-kD  fragment presum- 
ably disulfide bonded to intact chains are bound when the 
digest is applied to the heparin-agarose column and elnted 
with high salt. The attachment and spreading of cells on this 
fraction is  probably attributable  to  undegraded  thrombo- 
spondin.  The unbound fraction contains only the  140-kD 
fragment lacking the amino terminus (Fig. 5, lane d). This 
fraction supports cell attachment but only 6% of the cells 
spread on the 140-kD fragment. Similar results are obtained 
by digestion with 0.5 % wt/wt chymotrypsin at 25°C which 
also produces primarily the 140-kD  fragment (9). The un- 
bound fraction contains 140-kD and some 120-kD fragments 
(Fig. 5, lane f) and supports attachment but not spreading. 
The bound fraction contains the 25-kD heparin-binding frag- 
ment but lacks detectable intact thrombospondin and has no 
attachment activity. Heparin-binding fragment prepared by 
trypsin digestion is also inactive. Digestion with chymotryp- 
sin  at 37°C  results  in the  further cleavage of the  140-kD 
fragment to a  120-kD  fragment (Fig. 5, lane e) and loss of 
attachment activity. Digestion with 0.5 % wt/wt trypsin also 
produces primarily the  120-kD  fragment (Fig.  5,  lane b). 
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Figure 4.  Concentration  de- 
pendence  for  melanoma cell 
attachment and spreading on 
thrombospondin, laminin, and 
platelet factor 4. Bacteriologi- 
cal plastic disks were coated 
with the indicated concentra- 
tions of thrombospondin (TSP) 
(solid circles), lanfmin (open 
circles), platelet factor 4 (open 
triangles), or with  1  mg/ml 
BSA (solid triangles) in PBS/ 
Ca for 20 h at 4°C. The disks 
were incubated for 30 rain in 
Tris-BSA,  washed  twice  in 
RPMI  1640,  and  overlayed 
with  G361  melanoma  cells 
(5  x  104/cm  2) in RPMI 1640. 
After incubating for 90 rain at 
37°C,  unattached  ceils  were 
removed  by  washing.  The 
disks were removed by wash- 
ing. The disks were fixed with 
1% glutaraldehyde and stained 
with Giemsa. Attachment (A) 
and spreading (B) on throm- 
bospondin  are  presented  as 
mean  +  SD;  n  ---  12.  For 
laminin and platelet factor 4 
(C and D) results are mean + 
SD; n  =  4. 
This preparation has some attachment activity, probably due 
to 140-kD fragment, but no spreading activity. Further diges- 
tion using  5 %  wt/wt trypsin yields 90-,  105-,  and  ll0-kD 
fragments (Fig. 5,  lane c) which are also inactive. 
Antibody and Ligand Inhibition of  Melanoma 
Cell Attachment 
Four monoclonal antibodies to thrombospondin were exam- 
ined  for  their  effects  on  melanoma  attachment  to  throm- 
bospondin (Table II). Antibody C6.7 is a potent inhibitor of 
attachment,  even at the lowest concentrations tested.  This 
antibody is also a potent inhibitor of thrombin-induced plate- 
let aggregation (9) and binds to the 18-kD carboxyl-terminal 
region which is present on the  140-kD but not the  120-kD 
fragment of thrombospondin (9,  11). Antibody A6.1, which 
binds to the protease-resistant core of thrombospondin (6, 
11),  also  inhibits  melanoma  cell  attachment,  but  higher 
concentrations are required. Antibody A2.5, which binds to 
Table L G361 Melanoma Attachment to Thrombospondin Fragments 
Proteolytic digestion 
Major*  Not bound by heparin 
unbound 
fragment  Attached~  Spread 
Heparin bound 
Attached  Spread 
kD  cells~ram  2 
Trypsin 0.05%  wt/wt  180  0 
37°C, 60 min 
Trypsin 0.5% wt/wt  120  35  +  25 
37°C, 60 min  (140) 
Trypsin 5 % wt/wt  90  4  +  2 
37°C, 60 min  (105,110) 
Thrombin 4 U/ml  140  88 +  27 
37°C,  16 h 
Chymotrypsin 0.5%  wt/wt  140  80 +  13 
25°C, 30 min  (120) 
Chymotrypsin 0.5%  wt/wt  120  3 +  2 
37°C, 60 min 
% 
3+2 
0 
65:2 
5+2 
0 
cells~ram  ~ 
67  5:31 
0 
0 
77  +  24 
1_1 
0 
% 
735:9 
49+15 
0 
* Sizes of minor fragments are indicated in parenthesis. 
$ Control:  182  +  12 cells attached/mm  2, 78 +  1%  spread. 
The Journal of Cell Biology, Volume 104,  1987  134 Table II. Inhibition ofG361 Melanoma Cell Attachment 
to Thrombospondin  by Monoclonal Antibodies 
Antibody  Concentration  Attached  Spread 
#g/ml  cells~ram  2  % 
Control I  198  64 
A2.5  50  41  0 
20  55  2 
10  110  6 
5  111  11 
2.5  183  19 
A6.1  50  1  0 
20  17  7 
10  167  12 
5  175  21 
2.5  203  47 
D4.6  50  186  58 
Control II  308  41 
C6.7  50  1  0 
20  6  0 
10  51  12 
5  86  35 
2  90  33 
Figure 5. Limited proteolysis  of  thrombospondin. Thrombospondin 
was digested with thrombin, trypsin, or chymotrypsin, and frac- 
tionated on a hepadn-agarose column as described in Materials and 
Methods. SDS gel electrophoresis  was done on 7 % acrylamide  gels 
and stained with 0.1% Coornassie Blue.  Migration of molecular 
mass markers is indicated on the left. Lane a  is thrombospondin 
digested with 4 U/ml thrombin for 16 h at 37°C. Lanes b-fare frac- 
tions not bound on heparin-agarose  after thrombospondin digestion 
with 0.5 % wt/wt trypsin for 60 min at 37°C (b), 5 % wt/wt trypsin 
for 60 min at 37°C (c), 4 U/ml thrombin for 16 h at 37°C (d), 0.5 % 
wt/wt  chymotrypsin  for  60  min  at  37°C  (e),  or  0.5%  wt/wt 
chymotrypsin for 30 min at 25°C (f). 
the amino-terminal heparin-binding fragment (10, 11), only 
weakly inhibits attachment. Spreading, however, is inhibited 
70% at 2.5 Ixg/ml and completely inhibited at 50 Ixg/ml. This 
result is consistent with the observation that spreading activ- 
ity is lost after proteolytic removal of the heparin-binding 
fragment from thrombospondin.  Antibody D4.6 (6) has no 
effect on attachment or spreading at 50  l~g/ml. 
In  control  experiments,  the  specificity of the  antibody 
effects were examined using laminin or platelet factor 4  sub- 
strates. Neither A2.5 or C6.7 at 50 Ixg/ml inhibit attachment 
of G361  cells to platelet factor 4  (20  ~tg/ml), and C6.7 did 
not inhibit attachment or spreading of G361  cells on vitro- 
nectin (50 lxg/ml, data not shown).  The same antibodies at 
50  Ixg/ml  also  do  not  inhibit  attachment  to  laminin  (20 
Ixg/ml), although the cells spread on laminin extended fewer 
processes  in  the  presence  of both  antibodies  (results  not 
shown). 
Two monoclonal antibodies to vitronectin were also exam- 
ined as inhibitors of G361  cell attachment and spreading on 
thrombospondin and vitronectin. Antibody 8E6 (1:50 dilu- 
tion of ascites) completely inhibited G361 cell attachment to 
vitronectin (50  ~tg/ml) but had no effect on attachment or 
spreading on thrombospondin (50  lxg/ml). Attachment and 
spreading on thrombospondin were 80% and 86% of control 
levels, respectively. Antibody 9G2 did not inhibit attachment 
or spreading on either substrate. 
Monoclonal antibody OKM5 binds to C32 but not G361 
melanoma cells and inhibits adherence of erythrocytes para- 
sitized with falciparum malaria to C32 cells (4).  Antibody 
OKM5 at 10 lxg/ml does not inhibit attachment or spreading 
of either melanoma cell line on thrombospondin (Table III). 
Several ligands of thrombospondin were also examined as 
inhibitors (Table III). Fibrinogen binds to a site near the car- 
boxyl terminus of thrombospondin (7). Fibrinogen at 1 mg/ 
ml has no effect on attachment or spreading. Fucoidan and 
heparin are potent inhibitors of thrombospondin binding to 
sulfatides and erythrocyte agglutination (41).  Fucoidan and 
Table III. Inhibition of G361 Melanoma Cell Attachment 
to Thrombospondin 
Inhibitor  Concentration  Attachment*  Spreading* 
% of control  % of control 
Fibrinogen  0.1  mg/ml  98  +  19  102  +  17 
Fibrinogen  1 mg/ml  110  +  26  111  +  18 
Giy-Arg-Gly-Asp-Ser-Pro 0.68 mM  105  +  14  94  +  12 
Gly-Arg-Gly-Glu-Ser-Pro  0.83 mM  107  +  15  105  +  19 
Fucoidan  10 ~tg/ml  107  +  32  47  +  21 
Fucoidan  100 I~g/ml  41  ±  18  31  +  18 
Fucoidan  200  Ixg/ml  65  +  7  22  +  2 
Heparin  10 lag/ml  101  +  4  76  +  10 
Heparin  100 Ixg/ml  94  +  17  63  ±  16 
Antibody OKM5  10 stg/ml  100  ±  18  113  +  27 
* Mean  ±  SD, n  =  4,  with n  =  8  for control binding in the absence of in- 
hibitor. 
Roberts et al. Melanoma  Cell Attachment  to  Thrombospondin  135 Figure 6. Reversal of G361 melanoma cell spreading by monoclonal antibodies to thrombospondin.  G361 melanoma cells were plated in 
eight chamber Lab-Tek glass tissue culture slides at 1 x  104 cells per well in RPMI medium containing  10% FCS and grown for 48 h 
at 37°C. The medium was removed and replaced with RPMI (a and f) or RPMI containing 10 I~g/ml  of monoclonal antibodies to throm- 
bospondin:  A2.5  (b), A6.1 (c), C6.7 (d), or D4.6 (e). The cells were incubated at 37°C for 90 min and fixed with  1% glutaraldehyde. 
Photomicrographs  were taken using Hoffman modulation contrast optics.  Bar, 70 ~tm. 
heparin also selectively inhibit spreading of G361  cells on 
thrombospondin. Inhibition of spreading by heparin is less 
complete than  by  fucoidan.  Peptides  comprising the  cell 
attachment site of fibronectin (33) were also examined as in- 
hibitors  (Table III). Neither the  active sequence  Gly-Arg- 
Gly-Asp-Ser-Pro or  the  inactive  analog  Gly-Arg-Gly-Glu- 
Ser-Pro at 0.7  to 0.8  mM had any effect on attachment or 
spreading on thrombospondin substrates. 
Reversal of  Spreading 
The potential role in substrate attachment of thrombospondin 
either derived from serum in the growth medium or secreted 
by growing melanoma cells was examined by addition of the 
monoclonal antibodies to live G361 melanoma cells on glass 
slides (Fig.  6).  Antibodies A2.5 and C6.7  (10 lxg/ml)  both 
caused retraction of cell processes.  The rounded  cells re- 
mained attached to substrate. Antibody C6.7 induced retrac- 
tion equally in both sparse and confluent cultures, whereas 
the effect of A2.5 was greater in sparse cultures. Antibodies 
A6.1 and 134.6 had no effect on G361 melanoma cell cultures. 
The  cell  attachment  peptide  of fibronectin,  Gly-Arg-Gly- 
Asp-Ser-Pro,  causes  similar  rounding  and  detachment  of 
several cell lines from culture substrates (18). This peptide 
at 0.5 mM but not the analog Gly-Arg-Gly-Glu-Ser-Pro also 
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strate (results not shown). Some cells were detached after in- 
cubation with the peptide. 
Discussion 
Although thrombospondin is secreted by many cell lines in 
culture and is localized by antibodies (22, 23) and by uptake 
of radiolabeled protein (28) in the extracellular matrix, evi- 
dence for its function in cell adhesion is limited to aggrega- 
tion of thrombin- or ionophore-activated platelets (9, 13, 26) 
and adhesion of erythrocytes parasitized with falciparum 
malaria (42).  The present results demonstrate that throm- 
bospondin also mediates attachment and spreading of some 
human melanoma cell lines. Attachment and spreading of 
G361 melanoma cells on thrombospondin is similar to that 
obtained with the well-characterized cell adhesion protein, 
laminin (27). Attachment to both proteins is rapid and is fol- 
lowed by extensive spreading on the protein substrates (Fig. 
3).  Although C32 and G361 melanoma cells (Fig.  1) and 
some other cell lines (unpublished results) attach to throm- 
bospondin,  of those tested only the G361 melanoma cells 
spread on thrombospondin. 
The activity of thrombospondin is not due to contamina- 
tion with other proteins.  Several adhesive proteins are in 
platelet supernatants including fibronectin, platelet factor 4, 
and von Willebrand factor, von Willebrand factor does not 
promote attachment of G361  cells.  During purification of 
thrombospondin, fibronectin is removed by chromatography 
on gelatin-agarose and platelet factor 4  by gel  filtration. 
G361 melanoma cells spread on thrombospondin but not on 
platelet factor 4 substrates. Fibronectin peptides do not in- 
hibit adhesion to thrombospondin (Table III) but do inhibit 
cell attachment on fibronectin (33)  or vitronectin (18) and 
binding of fibronectin, fibrinogen, and von Willebrand factor 
to platelets (16, 35,  37). Finally, monoclonal antibodies to 
thrombospondin specifically  block attachment and spreading 
on thrombospondin but not on other proteins, whereas an an- 
tibody to vitronectin blocks attachment to vitronectin but not 
to thrombospondin. 
At least two regions of thrombospondin interact with G361 
melanoma cells. A site present in the 140-kD but not in the 
120-kD proteolytic fragments of thrombospondin is required 
for attachment. This region, which is near the carboxyl ter- 
minus (9) and is contained in the large globular domain seen 
by electron microscopy (11), is also implicated in binding to 
fibrinogen and thrombin-activated platelets. Antibody C6.7, 
which binds to this region and inhibits platelet aggregation 
(9),  strongly inhibits attachment of G361 cells to throm- 
bospondin (Table II). However, fibrinogen has no effect (Ta- 
ble III). The second important region is the amino-terminal 
heparin-binding site. This site is not required for attachment, 
as the  140-kD fragment lacks the heparin-binding site but 
strongly promotes attachment. Partial inhibition of attach- 
ment by high concentrations of  antibody A2.5 could be steric 
or result from a change in the conformation of thrombospon- 
din induced by this antibody (11). Proteolytic fragments lack- 
ing the heparin-binding domain do not promote spreading of 
G361 cells. Spreading is also inhibited by fucoidan and anti- 
body A2.5 which binds to this fragment. A third region may 
also interact with melanoma cells since antibody A6.1 in- 
hibits attachment. This antibody binds to the core region of 
thrombospondin (6) which contains a binding site for type 
V collagen (31). Fragments containing this region such as the 
120-kD fragment, however,  do not support attachment. In- 
teraction with this region may be weak or inhibition by A6.1 
could be due to steric effects. 
Multiple interactions between adhesive proteins and cells 
may be a general phenomenon. The attachment and spreading 
activities of laminin can be separated using proteolytic frag- 
ments (45). Multiple sites may also be involved in interaction 
of fibronectin with cells (1, 5). 
Inhibition of thrombospondin-mediated melanoma cell at- 
tachment and platelet aggregation by antibody C6.7 suggests 
that a common receptor for thrombospondin is on the two 
cell types. Based on antibody inhibition, fibrinogen, fibro- 
nectin, von Willebrand factor, and thrombospondin may bind 
to the glycoprotein llb/l/Ia complex on activated platelets 
(34, 47). Thrombospondin may also bind to a second class 
of receptor on resting platelets (47).  Binding of fibrinogen, 
fibronectin, and von Willebrand  factor to platelets is  in- 
hibited by Arg-Gly-Asp--containing  peptides  (16, 35),  and 
glycoprotein IIb/I/Ia incorporated in liposomes binds to this 
sequence (37). However, this receptor in liposomes does not 
bind to thrombospondin (37), and thrombospondin binds to 
thrombasthemic platelets lacking glycoprotein I/b/IHa (36). 
The present results demonstrate that attachment to throm- 
bospondin mediated by the receptor on G361 melanoma cells 
is not inhibited by an Arg-Gly-Asp-containing peptide. As 
parasitized erythrocytes adhere to C32 but not to G361 mela- 
noma cells (44),  thrombospondin may have different recep- 
tors on the two cell lines. The antigen defined by antibody 
OKM5  may be  a  receptor  for thrombospondin-mediated 
parasite adhesion on C32 cells (4) and for thrombospondin 
binding to C32 cells (2).  However,  OKM5 does not inhibit 
attachment or spreading of C32 or G361 cells (Table HI and 
our  unpublished  results).  Thus,  additional  receptors  for 
thrombospondin are probably present on both cell lines. Fur- 
ther work is required to identify these receptors and to deter- 
mine their relationship to the platelet receptor. 
Sulfated glycoconjugates  are a second class of receptors on 
melanoma cells for thrombospondin. The isolated heparin- 
binding domain does not support attachment but is required 
for spreading of  G361 cells (Table I). As platelet factor 4 does 
not promote spreading of G361 cells, however,  binding to 
heparin is not sufficient for promoting spreading. Throm- 
bospondin  binds  both  to  sulfated  polysaccharides  (e.g., 
heparin, [8]) and to sulfated glycolipids (41). The relative im- 
portance of sulfated glycolipids and heparan  sulfate pro- 
teoglycans in mediating spreading remains to be determined. 
Different distributions of sulfated glycolipids and proteogly- 
cans in C32 and G361 cells may account for their different 
spreading responses to thrombospondin. 
Because some antibodies to thrombospondin disrupt spread- 
ing of G361 melanoma cells growing on glass substrates, 
thrombospondin derived from serum in the medium or syn- 
thesized by these cells (42; Sherwood, J. A., D. D. Roberts, 
S. L. Spitalnik, K. Marsh, E. B. Harvey, J. W. Lawler, L. H. 
Miller, and R. J. Howard, manuscript in preparation) may 
function in substrate attachment during growth in culture. 
Deposition of labeled thrombospondin in extracellular ma- 
trix (28) and localization in endothelial cell matrices (19, 23) 
support this hypothesis. It is unlikely that the reversal of 
spreading is an indirect effect of antibody binding to throm- 
bospondin on the apical surface of the cells because not all 
antibodies to thrombospondin disrupt spreading. It is more 
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tween thrombospondin in the extracellular matrix and mela- 
noma surface receptors. As the fibronectin peptide Gly-Arg- 
Gly-Asp-Ser-Pro specifically induces rounding of G361 cells 
on glass  but does  not inhibit attachment or spreading  on 
thrombospondin, other serum proteins including fibronectin 
and vitronectin probably contribute to spreading (18).  The 
finding that antibodies to thrombospondin round up but do 
not detach G361 cells may be due to residual interaction or 
the melanoma cells with fibronectin and vitronectin on the 
glass  surface. 
Malignant melanoma can metastasize locally through epi- 
dermal basement membrane or distantly through blood or 
lymphatic vessels.  Melanoma cell interaction with adhesive 
molecules may play a role in metastasis (27). Because throm- 
bospondin is associated with endothelium in vivo (46), adhe- 
sion of melanoma cells to thrombospondin in subendothelial 
matrix may be important for passage of melanoma cells into 
circulation. If thrombospondin is on the lumenal surface of 
endothelial cells,  binding to thrombospondin could be  an 
early event in metastatic arrest. 
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